

Christian Domingo Ribas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1609120/publications.pdf>

Version: 2024-02-01

42
papers

1,470
citations

489802

18
h-index

371746

37
g-index

46
all docs

46
docs citations

46
times ranked

1701
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus on mild asthma management: results of a modified Delphi study. <i>Journal of Asthma</i> , 2023, 60, 145-157.	0.9	7
2	Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1835-1843.	2.0	4
3	Irritant-induced Asthma Caused by Aerotoxic Syndrome. <i>Lung</i> , 2021, 199, 165-170.	1.4	6
4	REal world Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. <i>Drugs</i> , 2021, 81, 1763-1774.	4.9	30
5	ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. <i>European Respiratory Journal</i> , 2020, 55, 1901136.	3.1	426
6	Dual Monoclonal Antibody Therapy for a Severe Asthma Patient. <i>Frontiers in Pharmacology</i> , 2020, 11, 587621.	1.6	18
7	As-needed ICS-LABA in Mild Asthma: What Does the Evidence Say?. <i>Drugs</i> , 2019, 79, 1729-1737.	4.9	23
8	New understanding in the treatment of cough (NEUROCOUGH) ERS Clinical Research Collaboration: improving care and treatment for patients with cough. <i>European Respiratory Journal</i> , 2019, 53, 1900787.	3.1	12
9	Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2277-2283.e2.	2.0	33
10	Cluster Analysis Identifies 3 Phenotypes within Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 955-961.e1.	2.0	18
11	A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 339-348.	1.1	21
12	Moving toward consensus on diagnosis and management of severe asthma in adults. <i>Current Medical Research and Opinion</i> , 2018, 34, 387-399.	0.9	9
13	Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. <i>ERJ Open Research</i> , 2018, 4, 00076-2018.	1.1	22
14	Precision medicine and aerosolization in mechanically ventilated adults. <i>Journal of Thoracic Disease</i> , 2018, 10, S3111-S3114.	0.6	2
15	The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation. <i>Respiratory Research</i> , 2018, 19, 189.	1.4	68
16	Airway reflux: an emerging topic in respiratory medicine. <i>Lancet Respiratory Medicine</i> , 2018, 6, 810-812.	5.2	6
17	The respiratory microbiome in bronchial mucosa and secretions from severe IgE-mediated asthma patients. <i>BMC Microbiology</i> , 2017, 17, 20.	1.3	20
18	Overlapping Effects of New Monoclonal Antibodies for Severe Asthma. <i>Drugs</i> , 2017, 77, 1769-1787.	4.9	32

#	ARTICLE	IF	CITATIONS
19	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	3.1	79
20	dlvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1328.	1.8	44
21	Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 521.	1.8	14
22	Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. <i>Clinical Therapeutics</i> , 2016, 38, 2058-2070.e1.	1.1	228
23	Tos crÃ³nica. <i>Archivos De Bronconeumologia</i> , 2015, 51, 579-589.	0.4	15
24	Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 492.	0.7	5
25	Omalizumab for Severe Asthma: Efficacy Beyond the Atopic Patient?. <i>Drugs</i> , 2014, 74, 521-533.	4.9	33
26	Ultra-LAMA, ultra-LABA, ultra-cortis? El futuro ya estÃ¡ aquÃ­. <i>Archivos De Bronconeumologia</i> , 2013, 49, 131-134.	0.4	6
27	Prevalence of Bronchiectasis in Asthma according to Oral Steroid Requirement: Influence of Immunoglobulin Levels. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	32
28	Induced Sputum Versus Exhaled Nitric Oxide for the Evaluation of Airway Inflammation in Allergic Pediatric Asthma Patients Treated With Omalizumab. <i>Chest</i> , 2013, 144, 761A.	0.4	1
29	Can Omalizumab Be Effective in Chronic Eosinophilic Pneumonia?. <i>Chest</i> , 2013, 143, 274.	0.4	24
30	Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. <i>Current Medical Research and Opinion</i> , 2011, 27, 45-53.	0.9	40
31	Effectiveness of unattended ambulatory sleep studies for the diagnosis and treatment of OSAS. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 26-31.	0.9	4
32	Optimal Clinical Time for Reliable Measurement of Transcutaneous CO2 with Ear Probes: Counterbalancing Overshoot and the Vasodilatation Effect. <i>Sensors</i> , 2010, 10, 491-500.	2.1	5
33	State-of-the-Art Sensor Technology in Spain: Invasive and Non-Invasive Techniques for Monitoring Respiratory Variables. <i>Sensors</i> , 2010, 10, 4655-4674.	2.1	13
34	Twelve yearsâ€™ experience with methotrexate for GINA treatment step 5 asthma patients. <i>Current Medical Research and Opinion</i> , 2009, 25, 367-374.	0.9	17
35	Design and Analysis of Health Products and Services: An Example at a Specialized COPD Unit. <i>Open Respiratory Medicine Journal</i> , 2008, 2, 7-15.	1.3	4
36	Capnometry in spontaneously breathing patients: the influence of chronic obstructive pulmonary disease and expiration maneuvers. <i>Medical Science Monitor</i> , 2008, 14, CR485-92.	0.5	10

#	ARTICLE	IF	CITATIONS
37	The Relevance of IgE in the Pathogenesis of Allergy: The Effect of an Anti-IgE Drug in Asthma and Other Diseases. Recent Patents on Inflammation and Allergy Drug Discovery, 2007, 1, 151-164.	3.9	16
38	Non-invasive home mechanical ventilation: Effectiveness and efficiency of an outpatient initiation protocol compared with the standard in-hospital model. Respiratory Medicine, 2007, 101, 1177-1182.	1.3	44
39	Neglected Respiratory Toxicity Caused by Cancer Therapy. Open Respiratory Medicine Journal, 2007, 1, 1-6.	1.3	6
40	Benefits of low weekly doses of methotrexate in steroid-dependent asthmatic patients. A double-blind, randomized, placebo-controlled study. Respiratory Medicine, 2006, 100, 411-419.	1.3	38
41	Home Oxygen Therapy for the 21st Century. Current Respiratory Medicine Reviews, 2006, 2, 237-251.	0.1	9
42	Evaluation of the Use of Three Different Devices for Nocturnal Oxygen Therapy in COPD Patients. Respiration, 1996, 63, 230-235.	1.2	11